Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Alvotech - Ordinary Shares (NQ: ALVO ) 13.64 -0.21 (-1.52%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 154,329 Open 13.80 Bid (Size) 13.60 (4) Ask (Size) 13.64 (4) Prev. Close 13.85 Today's Range 13.40 - 13.81 52wk Range 6.700 - 18.00 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe June 18, 2024 From Alvotech Via GlobeNewswire Alvotech and STADA add to strategic alliance through denosumab partnership June 11, 2024 From Alvotech Via GlobeNewswire Performance YTD +20.07% +20.07% 1 Month +1.04% +1.04% 3 Month -10.50% -10.50% 6 Month +25.25% +25.25% 1 Year +73.32% +73.32% More News Read More Alvotech Announces Strategic Refinancing Agreement June 07, 2024 From Alvotech Via GlobeNewswire ALVO Stock Earnings: Alvotech Reported Results for Q4 2023 March 20, 2024 Via InvestorPlace 2 Generic Drug Makers With Growing Runways May 31, 2024 Via MarketBeat Topics Intellectual Property Exposures Intellectual Property Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024 May 29, 2024 From Alvotech Via GlobeNewswire ALVO Stock Earnings: Alvotech Misses EPS for Q1 2024 May 21, 2024 Via InvestorPlace Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update May 21, 2024 From Alvotech Via GlobeNewswire Stocks Hold Steady On Mixed Fed Remarks, First Solar Rallies, Bitcoin Falls Below $70,000: What's Driving Markets Tuesday? May 21, 2024 Via Benzinga Topics Economy Exposures Interest Rates Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK May 21, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK May 21, 2024 From Alvotech Via GlobeNewswire Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. May 20, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. May 20, 2024 From Alvotech Via GlobeNewswire Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT) May 13, 2024 From Alvotech Via GlobeNewswire Alvotech Announces Participation at BofA Securities Healthcare Conference 2024 May 02, 2024 From Alvotech Via GlobeNewswire U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) April 30, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) April 30, 2024 From Alvotech Via GlobeNewswire Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab) April 24, 2024 From Alvotech Via GlobeNewswire Fifth Third Bancorp Reports Upbeat Earnings, Joins Metropolitan Bank Holding, Paramount Global And Other Big Stocks Moving Higher On Friday April 19, 2024 Via Benzinga Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab) April 19, 2024 From Alvotech Via GlobeNewswire Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) April 16, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) April 16, 2024 From Alvotech Via GlobeNewswire Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024 April 03, 2024 From Alvotech Via GlobeNewswire Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday March 25, 2024 Via Benzinga Topics Stocks Exposures US Equities Alvotech Announces Increase in Number of Own Shares March 22, 2024 From Alvotech Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
